Načítá se...
ACS Chemical Neuroscience Molecule Spotlight on Valdoxen
[Image: see text] A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT(2C) receptor.
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Chemical Society
2010
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3368641/ https://ncbi.nlm.nih.gov/pubmed/22778814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cn100062j |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|